Trials / Terminated
TerminatedNCT05638334
Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours
An Open Label, Multicentre, Positron Emission Tomography (PET) Imaging Study Using Zirconium-89 to Investigate the Biodistribution and Tumour Uptake of a PD-L1x4-1BB Bispecific Antibody (S095012) in Patients With Advanced Solid Tumours
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Institut de Recherches Internationales Servier · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the whole-body biodistribution and tumour uptake of 89Zr-S095012 in participants with solid tumours treated with S095012 (PD-L1x4-1BB bispecific antibody)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 89Zr-S095012 tracer and S095012 will be administered via an IV infusion | Imaging period 1 (Part A and Part B): The tracer will be administered with S095012 at non-therapeutic mass dose. The optimal mass dose of S095012 will be investigated in part A, and used in part B. Treatment period (Part A to C): S095012 will be administered with multiple 28 days- cycles in a Q2W schedule. Imaging period 2 (Part C): A second tracer dose will be administered at 1st treatment dose of S095012 in part C. |
Timeline
- Start date
- 2022-11-21
- Primary completion
- 2024-06-14
- Completion
- 2024-06-14
- First posted
- 2022-12-06
- Last updated
- 2026-02-17
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05638334. Inclusion in this directory is not an endorsement.